Sciwind Biosciences to Present Phase 3 Clinical Data on Ecnoglutide (GLP-1 analog) for Obesity and Type 2 Diabetes, and Preclinical Data on Novel Urocortin 2 Analog at ADA2025
HANGZHOU, China & SAN FRANCISCO, USA June 12th, 2025 – Sciwind Biosciences Co. Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that the company will present results from two pivotal Phase 3 clinical trials of ecnoglutide for obesity and type 2 diabetes, respectively, and preclinical data on a novel urocortin 2 analog, designed to preserve muscle mass and improve body composition, at the 85th Scientific Sessions of the American Diabetes Association’s (ADA), to be held in Chicago, USA, June 20 – 23, 2025.
Details of the presentations are as follows:
Title: A Phase 3 Evaluation of cAMP-Biased GLP-1 Analog Ecnoglutide in Adults with Overweight or Obesity
Presentation number: 164-OR
Presenter: Linong Ji, MD
Date/Time: June 21, 2025, 2:45 – 3:00 PM CDT
Session: Oral Presentations “So Long Prediabetes and Its Complications!”
Title: A Phase 3 Evaluation of cAMP-Biased GLP-1 Analog Ecnoglutide vs Dulaglutide in Adults with Type 2 Diabetes
Presentation number: 727-P
Presenter: Susan Xu, MD, PhD
Date/Time: June 23, 2025, 1:00 PM – 1:10 PM CDT
Session: ePoster Presentations “Learning across Diabetes”
and
Date/Time: June 22, 2025, 12:30 PM – 1:30 PM CDT
Session: General Poster Session
Title: Discovery of a Novel Long-Acting Urocortin 2 Analog for Improving Body Composition in Obese Mice
Presentation number: 1715-P
Presenter: Haixia Zou, PhD
Date/Time: June 23, 2025, 12:30 PM – 1:30 PM CDT
Session: General Poster Session
About Ecnoglutide
Ecnoglutide, discovered and developed by Sciwind Biosciences, is a first-in-class, long-acting GLP-1 receptor agonist engineered with a novel cAMP signaling bias to enhance biological efficacy and scalability. Designed for superior performance, ecnoglutide has successfully completed three Phase III clinical trials, supporting Marketing Authorization Applications in China for the treatment of adults with type 2 diabetes, as well as adults with obesity or overweight. From Phase I through Phase III, ecnoglutide has consistently demonstrated a favorable safety profile and strong tolerability, underscoring its potential as a transformative therapy in metabolic disease management.
About Urocortin 2 Analog
Urocortin 2 (UCN2) has shown promising potential to significantly reduce fat mass while enhancing lean muscle mass, positioning it as a compelling candidate for therapeutic strategies targeting metabolic health and body composition. XW4475, discovered by Sciwind Biosciences, is a novel, long-acting UCN2 analog designed for improved potency and selectivity. Preclinical studies in rodent models have demonstrated that XW4475 exhibits favorable pharmacokinetic profile and promising efficacy in reducing fat mass, preserving muscle mass, and improving overall body composition.
About Sciwind Biosciences
Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease. Sciwind has established a robust pipeline anchored by the lead asset, ecnoglutide (XW003), currently in the NDA stage in China. It has developed multiple proprietary technologies, including oral peptide and long-acting protein therapeutic delivery platforms and identified a series of drug candidates based on these core platform technologies. Sciwind has built an extensive pipeline targeting GLP-1 and synergistic mechanisms, offering both injectable and oral treatment solutions to deliver sustainable and high-quality treatment solutions for patients with metabolic conditions.
For more information, please visit www.sciwindbio.com.
Contacts
General Information: PR@sciwindbio.com
Business Development: BD@sciwindbio.com